SEARCH

SEARCH BY CITATION

FilenameFormatSizeDescription
epi12548-sup-0002-FigS1.tifimage/tif452KFig. S1. Study design.
epi12548-sup-0003-FigS2.tifimage/tif1057KFig. S2. Responder rate (≥50% reduction in 28-day seizure frequency from Study 312 baseline) and seizure freedom rate (100% reduction in 28-day seizure frequency from Study 312 baseline) during the open-label period (safety population).
epi12548-sup-0004-TableS1-S4.docWord document149K

Table S1. Patient demographics and baseline characteristics (safety population).

Table S2. (A) Tanner stages at baseline, study entry, and open-label visit 3 (weeks 40–43) and (B) transitions between Tanner stages (increases in one group) from baseline to study entry and open-label visit 3 (weeks 40–43; safety population).

Table S3. School Performance (safety population).

Table S4. Controlled Oral Word Association Test (patients with an intelligence quotient of at least 75; safety population).

epi12548-sup-0001-Guerrinietalslide.pptxapplication/pptx115K 

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.